# Noscendo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/noscendo

- Industry: Biotechnology
- Headquarters: Duisburg, Germany
- Website: www.noscendo.com
- Latest round: Series A (Apr 23, 2020)
- Investors on record: 5

## About

Noscendo GmbH specializes in innovative digital pathogen diagnostics, providing rapid and advanced detection capabilities for various infectious agents, enhancing clinical decision-making in healthcare settings.Founded in 2018 in Duisburg, Germany, Noscendo GmbH focuses on delivering advanced diagnostic solutions. The company was established by Peter Haug, who has a history in the biotech sector. Noscendo has completed a total of 2 deals, with its most recent funding round occurring on April 23, 2020, where it raised an undisclosed amount in SERIES A funding from new investors including Earlybird Venture Capital, JIH Family Office, and Paua Ventures, alongside returning investors High-Tech Gründerfonds and Wieland Capital.Noscendo GmbH primarily offers its flagship product, the DISQVER® platform, designed for digital pathogen diagnostics. This system enables the detection of over 16,000 microbes, including 1,500 recognized pathogens such as bacteria, viruses, fungi, and parasites, from a single patient sample within approximately 24 hours. Utilizing next-generation sequencing (NGS), DISQVER® analyzes cell-free DNA from the patient's blood, applying proprietary bioinformatics algorithms against a clinical-grade genome reference database. The platform is crucial for diagnosing bloodstream infections and sepsis, providing valuable insights to healthcare facilities, including regional hospitals and health insurance providers across Europe, particularly in Germany.Noscendo GmbH generates revenue primarily through its DISQVER® diagnostic services offered to healthcare institutions. Hospitals and clinics pay for the diagnostic tests conducted by the platform, with results provided within hours to aid timely treatment decisions. The transaction model is B2B, typically involving agreements with hospital systems or healthcare providers. Although specific pricing plans for DISQVER® are not disclosed, the service is likely structured on a per-test basis or through subscription agreements that facilitate ongoing access to its capabilities.Moving forward, Noscendo GmbH aims to enhance its product offerings and extend its market reach. The company is currently working on new diagnostic solutions, although specific products and release timelines have not been publicly detailed. Furthermore, Noscendo is strategizing an expansion into new geographic regions, with a focus on increasing its presence in international markets. The funding raised in April 2020 will be utilized to support these initiatives, strengthening the company's capabilities and improving access to its diagnostic technology for healthcare providers.

## Funding rounds

- Series A, Apr 23, 2020 — Earlybird, High-Tech Gruenderfonds, SquareOne, JIH Family Office, Wieland Capital

## Investors

- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- SquareOne (https://capitalatlas.ai/funds/squareone) — Series A
- JIH Family Office — Series A
- Wieland Capital (https://capitalatlas.ai/funds/wieland-capital) — Series A